Zynerba Pharmaceuticals (ZYNE) Releases Earnings Results, Beats Estimates By $0.21 EPS

Zynerba Pharmaceuticals (NASDAQ:ZYNE) released its earnings results on Monday. The company reported ($0.44) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.21, MarketWatch Earnings reports.

NASDAQ ZYNE opened at $4.86 on Tuesday. The firm has a market cap of $85.67 million, a P/E ratio of -1.96 and a beta of 4.98. Zynerba Pharmaceuticals has a fifty-two week low of $2.75 and a fifty-two week high of $12.50.

Several equities analysts recently weighed in on ZYNE shares. Zacks Investment Research upgraded Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.00 target price on the stock in a research report on Saturday, November 17th. HC Wainwright set a $23.00 target price on Zynerba Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, November 13th. Cantor Fitzgerald reiterated a “buy” rating and set a $11.00 target price on shares of Zynerba Pharmaceuticals in a research report on Thursday, March 7th. Finally, ValuEngine upgraded Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 5th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $13.38.

WARNING: This story was first published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://dakotafinancialnews.com/2019/03/12/zynerba-pharmaceuticals-zyne-releases-earnings-results-beats-estimates-by-0-21-eps.html.

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.

Recommended Story: Why is Cost of Capital Important?

Earnings History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.